Journal of Modern OncologyJournal of Modern OncologyСовременная онкология1815-14341815-1442LLC Obyedinennaya Redaktsiya26556ArticlesСтатьиResearch ArticleKhimioterapiya nemelkokletochnogo raka legkogo s ispol'zovaniem oksaliplatina(eloksatin)Химиотерапия немелкоклеточного рака легкого с использованием оксалиплатина(элоксатин)BychkovM BБычковМ БBol'shakovaS AБольшаковаС АBychkovYu MБычковЮ МРОНЦ им. Н.Н.Блохина РАМНРНЦРР МЗ и СР РФРНЦРР МЗ и СР РФРОНЦ им. Н.Н.Блохина РАМН1506200462VOL 6, NO2 (2004)ТОМ 6, №2 (2004)747809042020Copyright ©; 2004, Consilium MedicumCopyright ©; 2004, ООО "Консилиум Медикум"2004Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc/4.0https://modernonco.orscience.ru/1815-1434/article/view/26556

Рак легкого является проблемой номер один в современной онкологии. Он занимает первое место в России и мире как по заболеваемости, так и по смертности среди мужчин. Использование платиновых режимов позволило увеличить медиану выживаемости с 6 до 9 мес, а однолетнюю выживаемость с 25 до 45%. Современными стандартамихимиотерапии НМРЛ являются схемы, которые включают комбинации гемцитабина, таксола, таксотера, навельбина или этопозида с цисплатином или карбоплатином.В начале 90-х годов появились данные о новом препарате - оксалиплатине, который также является производным платины. На основании клинических исследований по изучению эффективности оксалиплатина, проведенных у более чем 200 больных с распространеннымНМРЛ, можно говорить об активности оксалиплатина при данном заболевании.

Kidani Y, Noji M, Tashiro T. Antitumor activity of Platinum (II) Complexes of 1,2-diaminocyclohexane isomers. Gann 1980; 71: 637-43.Boudny V, Vrana O, Gaycherov F et al. Biophysical activity of DNA Modified by 1,2-diaminocyclohexane Platinum (II) Complexes. Nucleic Acid Res 1992; 20: 267-72.In vitro and in vivo anrtitumor activity of oxaliplatin in combination with 5FU and other cytotoxic agents in human colorectal, ovarian and breast cancer cell lines. Debiopharm Internal Report, November 10, 1995.Boughattas N, Levi F, Fournier C et al. Report on the pharmacokinetics of L-OHP in mouse. ICIG Internal Report, May 1991.Urein S, Martiska M.C, Tillement J.P. In vitro binding of oxaliplatin to Human serum protein. Debiopharm Internal Report, October 1995.In vitro cytotoxicity - Protein binding - Red blood cell partitioning and biotransformation of oxaliplatin. J Cancer Research 1993; December 15: 5970-6.Pharmacokinetics of (1R,2R-diaminocyclohexane) oxaliplatinum (II) in comparison with cisplatin following a single intravenous injection in rabbits. Cancer Chemother Pharmacol 1993; 31: 475-80.Bastian G et al. Report on the pharmacokinetics of oxaliplatin in patients with normal and impaired renal function. Debiopharm Internal Report. Semptember 1994.Comparative analysis of cytotoxicity of anticancer drugs: preliminary studies with L-OHP. ICIG, Internal Report, March 23, 1990.Krikorian A, Vignoud J, Brienza S et al. General report on the tolerance of oxaliplatin. Debiopharm Internal Report, September 1994.Cappelaere P, Desaulty A. Comparative study of the auditory tolerance of oxaliplatin and cisplatin. Debiopharm Internal Report, July 1994.Gamelin K, Allain P. Pharmacokinetics behavour of oxaliplatin in repeated administration at 130 mg/m2 every three weeks. Debiopharm Internal Report, October 15, 1995.Misset J.L. Phase II-III study comparing oxaliplatin versus cisplatin in combination with cyclophisphamide in stage III and IV ovarian cancer. Second interim analysis. Sanofi Withrop Internal Report, March 1996.Monnet I, Brienza S, Voisin S et al. Phase II study of Oxaliplatin (L-OHP) in Locally adfvanced Non Small Cell Lung Cancer (NSCLC): Preliminary Results. Eur J Cancer 1993, 29A (suppl. 6); S163: Abst 901.Degardin M, Cappelaere P, Krakowski L et al. Phase II Trial of oxaliplatin (L-OHP) in Locally advanced Recurrebt and/or Metastatic Squamous Cell Carcinoma of Head anneck (SCCHN). Ann Oncol, November 1994; 5 (suppl. 8): 119, abst P596.Горбунова В. А. Расширение спектра терапевтических возможностей Оксалиплатина//Современная онкология. 2003; 4 (5): 3-6.Бесова Н.С. Применение Элоксатина при колоректальном раке и опухолях, чувствительных к производным платины. Материалы научно - практ. конференции онкологов Фед. упр. мед. - биол. проблем МЗ РФ. М., 2004; 37-40.Горбунова В.А., Топчиева С.В. Новые возможности химиотерапии солидных опухолей. Sanofi - synthelabo. М., 2004; с. 1-7.Monnet I, Brienza S, Hugert F et al. Phase II Study of oxaliplatin in poor - prognosis non - small cell lung cancer (NSCLC). Eur J Cancer 1998; 34 (7): 1124-7.Caussanel J.P, Levi F, Brienza S et al. Phase I trial of 5-day continuous venous infusion of Oxaliplatin at cardiac rhythm - modulated rate compared with constant rate. J Natl Cancer Inst 1990; 82: 1046-50.Levi F, Perpoint B, Garufi C et al. Oxaliplatin activity against m: a phase metastatic colorectal cancer: a phase II study of 5-day continuous venous infusion at cardiac rhythm -modulated rate. Eur J Cancer 1993; 29A: 1284-93.Levi F, Zidani R, Vannetzel J.M et al. Chronomodulated versus fixed - infusion - rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi - institutional trial. J Natl Cancer Inst 1994; 86: 1608-17.Monnet I, Soul P, de Cremoux H et al. Phase I/II study of escalation doses of vinorelbine in combination with oxaliplatin in patients with advanced non - small cell lung cancer. J Clin of Oncol 2001; 19: 458-63.Agelaki S, Kourousis C, Mavroudis D et al. A phase I study of docetaxel (D) and Oxaliplatin (L-OHP) as front - line treatment in metastatic breast cancer (MBC) and non - small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol Annu Meet. 36th Annual Meeting of American Society of Clinical Oncology. May 20-23. New Orleans, lousiana, USA 2000.Philip C Hoffaman J.D, Minegarden I.I, A.M Mauer et al. Phase II study of oxaliplatin (OX) and paclitaxel (PA) in advanced non - small cell lung cancer (NSCLC). 38th Annual Meeting of American Society of Clinical Oncology 2002, Abstr. 1321.Franciosi V, Barbieri R, Vasini G et al. A feasible combination of gemcitabine and oxaliplatin (GEM-OXAL) in patients with Advanced Non - small cell lung cancer/Preliminary Results of Phase II Study. 37th Annual Meeting of American Society of Clinical Oncology 2001, Abstr. 2804.Crino L, S Novello F. De Marinis et al. Gemcitabine - oxaliplatin (GEMOX) chemotherapy as first - line treatment in advanced non - small cell lung cancer (NSCLC): Preliminary results of multicenter phase II study. 39th Annual Meeting of American Society of Clinical Oncology 2003, Abstr. 2574.Scagliotti G, Kortsik C, Castellano D et al. Phase II randomized study of pemetrexed + carboplatin or oxaliplatin< as front - line chemotherapy in patients with locally advanced or metastatic non - small cell lung cancer. 39th Annual Meeting of American Society of Clinical Oncology 2003, Abstr. 2513.